Biotech Clinical Trials

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

Source: news.google.com

Published: Jun 24, 2026 12:24

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors BioSpace

Detailed source content is still being fetched from the original article. Use the source link above for the live story.

Courtesy Link

https://news.google.com/rss/articles/CBMiyAJBVV95cUxQMkpTbGw0OUxFRVFtNHdGcFNscDFubVVNdmpBRTdEbDhkNGM1ZW9IYlA0RndTam9tU1A5SmRJUUJnd3A3UHVIR1p3Zkdhb2J5RUNJLXRET0o5amNwb2lsMjRNdXk4Tjk2Rk9oeVhqVlN3OU1NUmp4bDNtLXFORXRBQmRHa29VYmpXZlc2UlUwNjk5dGRtTWhILTdFaThER0VpYWVFZjZlamQyMUx5ejVUdXBrRm9jczlEVkhoWEY0VXJRNVVkWEt5OXRqdTV4QU56OUdZWU8yUENDRUc0UE1tbGR0SlpzR0M0RWZhb3NnOG9VSmlnVGFPOXBTT0ZVMFp4bkxEQVhCNmNFeG4zWkRGNW5NbEhPODFHZFlpS3ItMEd6RjhBeFNweGlySGNMcWZneFVnLV9HNUE2TldrMy0wVVFsVUFzRG82?oc=5

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

More from this topic and section

Corxel to advance oral obesity drug to Phase III trials

RQ Bio reels in $115M to take long-acting flu prevention antiviral into clinic

From Trial-and-Error to Targeted Success: How Computational Disease Models Can Help Patients and Pharma Companies

3 Companies Redefining Healthcare Innovation

Health Innovation Roundup

Osanni Bio raises $190 million Series B to advance therapeutics platform

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

More from this topic and section

Corxel to advance oral obesity drug to Phase III trials

RQ Bio reels in $115M to take long-acting flu prevention antiviral into clinic

From Trial-and-Error to Targeted Success: How Computational Disease Models Can Help Patients and Pharma Companies

3 Companies Redefining Healthcare Innovation

Health Innovation Roundup

Osanni Bio raises $190 million Series B to advance therapeutics platform

Add Newsfeed to your home screen